Back to search results

Magic Ink for Radiation Treatment Delivery in Breast Cancer

This study is testing a new type of tattoo ink, called Magic Ink, for guiding radiation treatment in women with breast cancer. This ink is only visible under ultraviolet light and can be hidden with white light. The main goal is to see if Magic Ink is as safe as the standard tattoo ink currently used and if it remains visible for radiation therapists during treatment. You may be able to join if you are an adult woman diagnosed with stage 0, I, II, or III breast cancer and are planning to have radiation therapy after surgery. The study plans to enroll 30 participants, but its current status is unclear.

Study design
This is an interventional study enrolling 30 participants. It compares Magic Ink to standard tattoo ink for radiation guidance.
What's involved
You would receive a Magic Ink tattoo, complete a body image survey, and have skin assessments before radiation, after the first week of radiation, and 3 months later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety for 3 months after completing radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07095114

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Recruiting
NAAges 18+InterventionalTreatment
Barbara Ann Karmanos Cancer Institute
~30 participants
Updated 2025-09-18 on ClinicalTrials.gov
What's tested:Magic Ink

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of Magic Ink
Measured over 3 months after completion of Radiation Therapy

Conditions

Ductal Carcinoma in Situ
Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer

Explore related trials

Breast CarcinomaBreast Ductal Carcinoma In Situ

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Michael Dominello, DO · PRINCIPAL_INVESTIGATOR · Wayne State University

Who to contact

Michael Dominello, DO
[email protected]
3135769546
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
Participants must be 18 years of age or older
Participant must be able to understand a written informed consent document and be willing to sign it
Participant must be assigned female at birth
Participant must have a Karnofsky performance score of greater than or equal to 70%
Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:
Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
Agree to practice true abstinence from sexual intercourse
Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6

Exclusion

Participants who have received prior radiation treatment to the affected breast.
Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

What this trial measures

  • Safety of Magic Ink3 months after completion of Radiation Therapy

    Number of participants with treatment related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)